IL-15 Inhibitors
The chemical class of IL-15 inhibitors comprises a diverse set of compounds that exert inhibitory effects on interleukin-15 (IL-15) through direct or indirect mechanisms. These inhibitors target key components of IL-15 signaling pathways, disrupting downstream events and ultimately modulating IL-15-mediated cellular responses and immune functions. AMG 714, for example, serves as a direct IL-15 inhibitor by targeting the IL-15 receptor complex, impeding the binding of IL-15 to its receptor and preventing subsequent signaling events. On the other hand, sc-514 acts indirectly by modulating the NF-κB signaling pathway, inhibiting IκB kinase and decreasing NF-κB activation. Since IL-15 signaling involves NF-κB, this indirect inhibition disrupts IL-15-mediated cellular responses. Compounds like AZD1208, Tofacitinib, and Filgotinib function as indirect IL-15 inhibitors by targeting the JAK/STAT signaling pathway. They inhibit JAK1 and JAK3, key components of IL-15 signaling, leading to downregulated STAT phosphorylation and transcriptional activity. Similarly, Ruxolitinib and Baricitinib modulate the JAK/STAT pathway to achieve indirect IL-15 inhibition.
Other inhibitors like TPCA-1 and BAY 11-7082 act indirectly by influencing the NF-κB signaling pathway. They inhibit IKK-2, leading to decreased NF-κB activation, which, in turn, disrupts IL-15-mediated cellular responses. SP600125 serves as an indirect IL-15 inhibitor by targeting the JNK signaling pathway, inhibiting JNK and downregulating JNK-mediated cellular responses. S3I-201, another indirect inhibitor, modulates the JAK/STAT signaling pathway by inhibiting STAT3, a crucial component of IL-15 signaling. Lastly, Fludarabine phosphate acts indirectly by targeting the PI3K/Akt signaling pathway, inhibiting PI3K and decreasing Akt activation, thereby modulating IL-15-mediated cellular responses. In summary, the chemical class of IL-15 inhibitors encompasses a range of compounds with distinct mechanisms of action, collectively providing valuable tools for understanding and manipulating IL-15 signaling in the context of cellular responses and immune functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SC514 | 354812-17-2 | sc-205504 sc-205504A | 5 mg 10 mg | $67.00 $91.00 | 13 | |
SC-514 serves as an indirect IL-15 inhibitor by modulating the NF-κB signaling pathway. It inhibits IκB kinase, leading to decreased NF-κB activation. Since IL-15 signaling involves NF-κB, the inhibition of this pathway indirectly modulates IL-15-mediated cellular responses and immune functions. | ||||||
AZD1208 | 1204144-28-4 | sc-503188 | 10 mg | $322.00 | 1 | |
AZD1208 acts as an indirect IL-15 inhibitor by targeting the JAK/STAT signaling pathway. It inhibits JAK1 and JAK3, key components of IL-15 signaling. This inhibition downregulates STAT phosphorylation and transcriptional activity, indirectly modulating IL-15-mediated cellular responses and immune functions. | ||||||
Filgotinib | 1206161-97-8 | sc-507393 | 10 mg | $150.00 | ||
Filgotinib serves as an indirect IL-15 inhibitor by targeting the JAK/STAT signaling pathway. It inhibits JAK1 and JAK3, key components of IL-15 signaling. This inhibition downregulates STAT phosphorylation and transcriptional activity, indirectly modulating IL-15-mediated cellular responses and immune functions. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib acts as an indirect IL-15 inhibitor by modulating the JAK/STAT signaling pathway. It inhibits JAK1 and JAK3, key components of IL-15 signaling. This inhibition downregulates STAT phosphorylation and transcriptional activity, indirectly modulating IL-15-mediated cellular responses and immune functions. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib functions as an indirect IL-15 inhibitor by modulating the JAK/STAT signaling pathway. It inhibits JAK1 and JAK3, key components of IL-15 signaling. This inhibition downregulates STAT phosphorylation and transcriptional activity, indirectly modulating IL-15-mediated cellular responses and immune functions. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
IKK-2 Inhibitor IV (TPCA-1) serves as an indirect IL-15 inhibitor by modulating the NF-κB signaling pathway. It inhibits IKK-2, leading to decreased NF-κB activation. Since IL-15 signaling involves NF-κB, the inhibition of this pathway indirectly modulates IL-15-mediated cellular responses and immune functions. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 acts as an indirect IL-15 inhibitor by modulating the NF-κB signaling pathway. It inhibits IKK-2, leading to decreased NF-κB activation. Since IL-15 signaling involves NF-κB, the inhibition of this pathway indirectly modulates IL-15-mediated cellular responses and immune functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 serves as an indirect IL-15 inhibitor by targeting the JNK signaling pathway. It inhibits JNK, a kinase involved in IL-15 signaling. This inhibition downregulates JNK-mediated cellular responses, indirectly modulating IL-15-mediated immune functions. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $151.00 | 104 | |
S3I-201 acts as an indirect IL-15 inhibitor by modulating the JAK/STAT signaling pathway. It inhibits STAT3, a key component of IL-15 signaling. This inhibition downregulates STAT3 phosphorylation and transcriptional activity, indirectly modulating IL-15-mediated cellular responses and immune functions. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $58.00 $204.00 | 15 | |
Fludarabine phosphate serves as an indirect IL-15 inhibitor by modulating the PI3K/Akt signaling pathway. It inhibits PI3K, leading to decreased Akt activation. Since IL-15 signaling involves Akt, the inhibition of this pathway indirectly modulates IL-15-mediated cellular responses and immune functions. | ||||||